Vivimed – Recall of losartan
May 3, 2019 - Vivimed announced a voluntary consumer-level recall of 19 lots of losartan tablets due to the detection of an impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), that is above the FDA’s interim acceptable exposure limit of 9.82 ppm.
Download PDF
